IO Biotech Announces 2023 Second Quarter Results
11 août 2023 08h30 HE
|
IO Biotech
Achieved significant enrollment milestone in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in advanced melanoma; full enrollment anticipated by the end of 2023Initiated enrollment in three...
IO Biotech Appoints Heidi Hunter to its Board of Directors
11 août 2023 08h05 HE
|
IO Biotech
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
08 août 2023 08h05 HE
|
IO Biotech
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech, Inc. Announces $75 Million Private Placement Financing
07 août 2023 08h30 HE
|
IO Biotech
Offering includes participation from both new and existing healthcare-dedicated investorsProceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, Aug. 07, 2023 (GLOBE...
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
28 juil. 2023 08h05 HE
|
IO Biotech
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...
IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer
25 juil. 2023 16h05 HE
|
IO Biotech
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
18 juil. 2023 16h05 HE
|
IO Biotech
Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone
14 juin 2023 08h00 HE
|
IO Biotech
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced melanoma; trial protocol calls for an interim analysis of...
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
01 juin 2023 08h30 HE
|
IO Biotech
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...
IO Biotech to Present at the Jefferies Healthcare Conference
30 mai 2023 16h35 HE
|
IO Biotech
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology...